英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
wagonman查看　wagonman　在百度字典中的解释百度英翻中〔查看〕
wagonman查看　wagonman　在Google字典中的解释Google英翻中〔查看〕
wagonman查看　wagonman　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years . . .
    The five-year results for Libtayo plus chemotherapy presented at WCLC add to the breadth of long-term data for Libtayo in advanced NSCLC, including five-year outcomes from the EMPOWER-Lung 1 trial that were presented at WCLC 2024 confirming durable survival benefit as monotherapy
  • Treatment in Advanced NSCLC | LIBTAYO® (cemiplimab-rwlc)
    or your lung cancer has spread to other areas of your body (metastatic lung cancer), and your tumor does not have an abnormal “EGFR,” “ALK,” or “ROS1” gene LIBTAYO may be used as your first treatment: In combination with chemotherapy that contains a platinum medicine, or alone if your tumor tests positive for high “PD-L1 ”
  • LIBTAYO® (cemiplimab-rwlc) in Advanced NSCLC
    LIBTAYO in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is locally advanced where patients are not candidates for surgical resection or definitive chemoradiation OR metastatic
  • Phase III EMPOWER-Lung 3 Trial Confirms Five-Year Survival . . .
    Regeneron has shared positive, long-term overall survival (OS) data from the Phase III EMPOWER-Lung 3 clinical trial (NCT03409614), which assessed Libtayo (cemiplimab) along with platinum-based chemotherapy versus chemotherapy alone as a first-line treatment for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with no EGFR, ALK, or ROS1 aberrations 1 Long-term
  • Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell . . .
    First-line therapy for advanced non–small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy Among patients with a tumor proportion score for programmed
  • LIBTAYO works with your immune system to help treat advanced . . .
    Has spread to other areas of the body (metastatic lung cancer) Biomarker testing is needed before you start treatment Biomarker testing helps determine if treatment with LIBTAYO is appropriate for you based on your PD-L1 levels and if you tested negative for abnormal EGFR, ALK, or ROS1 genes
  • How Libtayo Works for Non-Small-Cell Lung Cancer - WebMD
    Libtayo may also be used along with a platinum-based chemotherapy as an initial (first-line) treatment for advanced or metastatic NSCLC that does not have other targetable mutations of EGFR, ALK
  • Connecting the Dots: the ALK lung cancer breakthrough
    As multiple ALK inhibitors became available, a new question emerged: which drug should be used first, and how should therapy be sequenced after resistance develops? In 2018, Dr Satoshi Yoda at Massachusetts General Hospital received LCRF funding to study how to tailor treatment for ALK-positive lung cancer
  • A FIRST-LINE TREATMENT OPTION IN ADVANCED NSCLC
    ADVANCED NSCLC LIBTAYO is indicated for the first-line treatment of patients with non–small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression [tumor proportion score (TPS) ≥50%] as determined by an FDA-approved test, with no EGFR, ALK, or ROS1 aberrations, and is1:
  • FDA approves cemiplimab-rwlc in combination with platinum . . .
    On November 8, 2022, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc ) in combination with platinum-based chemotherapy for adult patients with





中文字典-英文字典  2005-2009